GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. GH Research PLC stands ninth among them.

GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing innovative therapies for treatment-resistant depression (TRD) and other psychiatric and neurological disorders. Its lead candidate, GH001, is an inhalable mebufotenin product currently in Phase 2b trials for TRD, with additional Phase 2a studies targeting bipolar II disorder and postpartum depression. The company is also developing GH002 and GH003, intravenous and intranasal formulations, to expand treatment options for neurological conditions.

Recent developments highlight significant clinical progress. The Phase 2b trial of GH001 reported a 73% remission rate at six months with infrequent treatments and no psychotherapy required, alongside a strong safety profile with no serious adverse events. GH Research is addressing the FDA’s remaining clinical hold on its Investigational New Drug (IND) application, aiming to submit a full response by mid-2025 and preparing for a global pivotal clinical program in 2026. Positive Phase 1 results for GH002 further support the company’s expansion strategy, with an IND submission planned for Q4 2025, positioning it among the best psychedelic stocks in the market.

GH Research PLC (NASDAQ:GHRS) has actively shared clinical data at major conferences, including the American Society of Clinical Psychopharmacology Annual Meeting 2025, demonstrating GH001’s efficacy across multiple psychiatric disorders. Preparations for pivotal trials are ongoing, with contract research organization selection and regulatory strategies advancing in parallel.

While we acknowledge the potential of GHRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.